MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-21-2026
Aurora Cannabis Retained Earnings 2011-2026 | ACB
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Aurora Cannabis
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | -3.59 B | -99.2 M | 126 M | -12.2 M | -16.9 M | -11.3 M | -1.53 M | -1.33 M | -937 K | -688 K |
All numbers in CAD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 126 M | -3.59 B | -361 M |
Quarterly Retained Earnings Aurora Cannabis
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | -4.32 B | - | - | - | -3.6 B | - | - | - | -286 M | - | - | - | 87.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in CAD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 87.7 M | -4.32 B | -2.03 B |
Retained Earnings of other stocks in the Drug manufacturers industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
-1.15 B | - | - | $ 754 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
-457 M | - | 7.5 % | $ 6.35 M | USA |
 |
Catalent
CTLT
|
-781 M | - | - | $ 11.5 B | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-305 M | - | 0.86 % | $ 117 M | USA |
 |
DURECT Corporation
DRRX
|
-589 M | - | - | $ 50.1 M | USA |
 |
Canopy Growth Corporation
CGC
|
-10.9 B | $ 1.1 | 3.77 % | $ 118 M |  Canada |
 |
Endo International plc
ENDP
|
-15.4 B | - | - | $ 28.9 M |  Irlanda |
 |
Agile Therapeutics
AGRX
|
-423 M | - | 10.11 % | $ 58.2 M | USA |
 |
Evoke Pharma
EVOK
|
-123 M | - | - | $ 36.6 M | USA |
 |
Alimera Sciences
ALIM
|
-418 M | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
1.06 B | $ 2.66 | 2.12 % | $ 1.35 B | Canada |
 |
Evolus
EOLS
|
-661 M | $ 5.46 | 32.2 % | $ 352 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-794 M | - | - | $ 2.06 B |  France |
 |
Jupiter Wellness
JUPW
|
-115 M | - | - | $ 33.6 M | USA |
 |
China Pharma Holdings
CPHI
|
-44 M | $ 0.57 | 3.55 % | $ 9.95 M |  China |
 |
Cumberland Pharmaceuticals
CPIX
|
-24 M | $ 4.58 | - | $ 64.4 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-1.43 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-659 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
-187 M | - | - | $ 193 M | Canada |
 |
Athenex
ATNX
|
-1.02 B | - | -23.39 % | $ 1.76 M | USA |
 |
Harrow Health
HROW
|
-157 M | $ 39.84 | 3.2 % | $ 1.46 B | USA |
 |
Emergent BioSolutions
EBS
|
-21.8 M | $ 8.88 | -0.34 % | $ 455 M | USA |
 |
ProPhase Labs
PRPH
|
11.8 M | - | - | $ 5.07 M | USA |
 |
Assertio Holdings
ASRT
|
-652 M | $ 11.86 | -0.29 % | $ 842 M | USA |
 |
Radius Health
RDUS
|
-1.37 B | - | - | $ 1.42 B | USA |
 |
Bausch Health Companies
BHC
|
-9.78 B | $ 5.63 | -1.66 % | $ 2.05 B | Canada |
 |
Lannett Company
LCI
|
-596 M | - | 1.15 % | $ 7.11 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
112 M | - | -39.89 % | $ 27.7 M | USA |
 |
Organogenesis Holdings
ORGO
|
-40.1 M | $ 2.89 | 0.7 % | $ 381 M | USA |
 |
OrganiGram Holdings
OGI
|
-145 M | $ 1.4 | 1.85 % | $ 402 M | Canada |
 |
Rockwell Medical
RMTI
|
-397 M | $ 0.89 | -1.05 % | $ 20.8 M | USA |
 |
Perrigo Company plc
PRGO
|
-3.68 B | $ 11.57 | 1.62 % | $ 1.6 B | USA |
 |
Sundial Growers
SNDL
|
-565 M | $ 1.55 | 0.98 % | $ 3.37 M | Canada |
 |
Veru
VERU
|
-295 M | $ 2.56 | 1.39 % | $ 345 M | USA |
 |
Viatris
VTRS
|
5.18 B | $ 14.89 | -0.03 % | $ 17.9 B | USA |
 |
cbdMD
YCBD
|
-182 M | $ 0.76 | -2.68 % | $ 3.28 M | USA |
 |
TherapeuticsMD
TXMD
|
-950 M | $ 2.3 | 3.57 % | $ 24 M | USA |
 |
Pacira BioSciences
PCRX
|
-206 M | $ 22.11 | 0.05 % | $ 1.02 B | USA |
 |
PetIQ
PETQ
|
-161 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
-720 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
-148 M | - | -27.8 % | $ 2.56 M | USA |
 |
Recro Pharma
REPH
|
-279 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
-561 M | $ 4.66 | -0.32 % | $ 140 M | USA |
 |
SCYNEXIS
SCYX
|
-355 M | $ 0.75 | -0.27 % | $ 35.9 M | USA |
 |
Solid Biosciences
SLDB
|
-783 M | $ 5.96 | 0.02 % | $ 243 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-198 M | $ 2.75 | - | $ 3.41 M | USA |
 |
Tricida
TCDA
|
-810 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
-2.42 B | $ 7.53 | 2.31 % | $ 4.65 B | Canada |
 |
Zynerba Pharmaceuticals
ZYNE
|
-275 M | - | - | $ 55.5 M | USA |